Ratings by Stifel (Dara Azar)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/8/2026 | Enliven Therapeutics | ELVN | New Coverage | Buy (N/A) |
34.71 (48.60) |
40.02% | Details | |
| 6/2/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (Buy) |
|
Details | ||
| 6/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (Buy) |
|
Details | ||
| 5/15/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 4/17/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (Buy) |
|
Details | ||
| 4/7/2026 | Inhibrx Biosciences | INBX | New Coverage | Buy (N/A) |
63.72 (92.91) |
45.81% | Details | |
| 4/7/2026 | Summit Therapeutics plc | SMMT | New Coverage | Buy (N/A) |
18.69 (14.25) |
-23.76% | Details |
